Stories
Eli Lilly's Foundayo Obesity Pill Eyes 2027 India Launch, Awaiting Approval
M
Moneycontrol•02-10-2026, 10:03
Eli Lilly's Foundayo Obesity Pill Eyes 2027 India Launch, Awaiting Approval
- •Eli Lilly plans to launch its oral obesity drug Foundayo (orforglipron) in India by 2027, pending regulatory approval, according to CEO David Ricks.
- •Foundayo, a once-daily GLP-1 receptor agonist, was approved by the US FDA in April 2026 for long-term weight management in adults.
- •Lilly is leveraging Indian manufacturing partners for global supply and is compressing the gap between international and Indian drug introductions to about one year.
- •The company is fulfilling a $1 billion India investment through contract manufacturing partnerships and a manufacturing and quality technical hub.
- •Lilly aims for India to become one of its top five markets, expanding clinical trials and access to cardiometabolic treatments.
Key Questions Answered
Eli Lilly's oral obesity drug Foundayo could reach India in 2027, pending regulatory approval from Indian authorities.
Foundayo is the brand name for orforglipron, which is a once-daily, small-molecule GLP-1 receptor agonist approved for long-term weight management in adults with obesity or overweight alongside diet and physical activity.
Eli Lilly is implementing its $1 billion investment through contract manufacturing partnerships and technical capabilities, working alongside Indian laboratory partners to scale production and establish a manufacturing hub.
